がん治療薬・支持療法薬市場：がんタイプ別、薬剤クラス別-2023-2030年の世界予測

がん治療薬・支持療法薬の世界市場は、2023年にCAGR 10.53%で3,026億5,000万米ドルと予測され、2030年には6,107億2,000万米ドルに達するという驚異的な成長を遂げると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のがん治療薬・支持療法薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーが特定のニーズに基づいて情報に基づいた意思決定を行えるようにします。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の発売、未開拓地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.がん治療薬・支持療法薬の世界市場規模および予測は？

2.予測期間中、世界のがん治療薬・支持療法薬市場を形成するCOVID-19の阻害要因と影響は？

3.がん治療薬・支持療法薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.がん治療薬・支持療法薬の世界市場における競争戦略は？

5.がん治療薬・支持療法薬の世界市場における技術動向と規制の枠組みは？

6.がん治療薬・支持療法薬の世界市場における主要ベンダーの市場シェアは？

7.がん治療薬・支持療法薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん患者の罹患率の増加
    • 新薬や治療法の開発におけるイノベーション
    • 非侵襲的治療に対する需要の高まり
  • 抑制要因
    • 高額な抗がん剤
  • 機会
    • がん治療のための継続的なイノベーション
    • バイオシミラーおよび生物製剤の臨床試験および開発
  • 課題
    • 限られた払い戻しオプション
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 がん治療薬・支持療法薬市場がんの種類別

• 乳がん
• 肺がん
• 黒色腫
• 前立腺がん

第7章 がん治療薬・支持療法薬市場薬物クラス別

• 制吐薬
• ビスホスホネート
• エリスロポエチン刺激剤
• 顆粒球コロニー刺激因子
• 非ステロイド性抗炎症薬
• オピオイド

第8章 南北アメリカのがん治療薬・支持療法薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域のがん治療薬・支持療法薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのがん治療薬・支持療法薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第12章 掲載企業一覧

第13章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2022 VS 2030 (%)
• FIGURE 5. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
• FIGURE 6. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET DYNAMICS
• FIGURE 8. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 5. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 10. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIETIN-STIMULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 22. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 23. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 24. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 26. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 34. AUSTRALIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 36. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 37. INDIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 38. INDIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 40. INDONESIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 42. JAPAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 44. MALAYSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 46. PHILIPPINES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 48. SINGAPORE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 50. SOUTH KOREA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 52. TAIWAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 54. THAILAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 56. VIETNAM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 61. DENMARK CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 63. EGYPT CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 65. FINLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 67. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 69. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 71. ISRAEL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 72. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 73. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 75. NETHERLANDS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 77. NIGERIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 79. NORWAY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 80. POLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 81. POLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. QATAR CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 83. QATAR CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 85. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SAUDI ARABIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 91. SPAIN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 93. SWEDEN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 95. SWITZERLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 97. TURKEY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 99. UNITED ARAB EMIRATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 101. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 102. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 103. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 104. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET LICENSE & PRICING

The Global Cancer Therapeutics & Supportive Care Drugs Market is forecasted to grow significantly, with a projected USD 302.65 billion in 2023 at a CAGR of 10.53% and expected to reach a staggering USD 610.72 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cancer Therapeutics & Supportive Care Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cancer Therapeutics & Supportive Care Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Cancer Type, market is studied across Breast Cancer, Lung Cancer, Melanoma, and Prostate Cancer. The Breast Cancer is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Antiemetics, Bisphosphonates, Erythropoietin-Stimulating Agents, Granulocyte-Colony Stimulating Factors, Nonsteroidal Anti-Inflammatory Drugs, and Opioids. The Nonsteroidal Anti-Inflammatory Drugs is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cancer Therapeutics & Supportive Care Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cancer Therapeutics & Supportive Care Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Therapeutics & Supportive Care Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Therapeutics & Supportive Care Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Cancer Therapeutics & Supportive Care Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Cancer Therapeutics & Supportive Care Drugs Market?

6. What is the market share of the leading vendors in the Global Cancer Therapeutics & Supportive Care Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Cancer Therapeutics & Supportive Care Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Cancer Therapeutics & Supportive Care Drugs Market, by Cancer Type, 2022 vs 2030
• 4.3. Cancer Therapeutics & Supportive Care Drugs Market, by Drug Class, 2022 vs 2030
• 4.4. Cancer Therapeutics & Supportive Care Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cancer patients
    • 5.1.1.2. Innovations in the development of new drugs and therapies
    • 5.1.1.3. Growing demand for non-invasive therapies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of cancer drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing innovations for the treatment of cancer
    • 5.1.3.2. Clinical trials and developments of biosimilars and biologics
  • 5.1.4. Challenges
    • 5.1.4.1. Limited reimbursement options
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Cancer Therapeutics & Supportive Care Drugs Market, by Cancer Type

• 6.1. Introduction
• 6.2. Breast Cancer
• 6.3. Lung Cancer
• 6.4. Melanoma
• 6.5. Prostate Cancer

7. Cancer Therapeutics & Supportive Care Drugs Market, by Drug Class

• 7.1. Introduction
• 7.2. Antiemetics
• 7.3. Bisphosphonates
• 7.4. Erythropoietin-Stimulating Agents
• 7.5. Granulocyte-Colony Stimulating Factors
• 7.6. Nonsteroidal Anti-Inflammatory Drugs
• 7.7. Opioids

8. Americas Cancer Therapeutics & Supportive Care Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Cancer Therapeutics & Supportive Care Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Cancer Therapeutics & Supportive Care Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing